Cancers 2010, 2(2), 721-739; doi:10.3390/cancers2020721
Review

Biomarkers of the Metabolic Syndrome and Breast Cancer Prognosis

1, 1,* email and 2,* email
Received: 23 March 2010; in revised form: 13 April 2010 / Accepted: 26 April 2010 / Published: 28 April 2010
(This article belongs to the Special Issue Biomarkers: Oncology Studies)
View Full-Text   |   Download PDF [233 KB, uploaded 28 April 2010]
Abstract: In spite of its public health importance, our understanding of the mechanisms of breast carcinogenesis and progress is still evolving. The metabolic syndrome (MS) is a constellation of biochemical abnormalities including visceral adiposity, hyperglycemia, hyperinsulinemia, dyslipidemia and high blood pressure. The components of the MS have all been related to late-stage disease and even to a poor prognosis of breast cancer through multiple interacting mechanisms. In this review, we aim to present a summary of recent advances in the understanding of the contribution of the MS to breast cancer with the emphasis on the role of biomarkers of the MS in the prognosis of breast cancer.
Keywords: metabolic syndrome; breast cancer; epidemiology; biomarkers; prognosis
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Export to BibTeX |
EndNote


MDPI and ACS Style

Zhu, Q.-L.; Xu, W.-H.; Tao, M.-H. Biomarkers of the Metabolic Syndrome and Breast Cancer Prognosis. Cancers 2010, 2, 721-739.

AMA Style

Zhu Q-L, Xu W-H, Tao M-H. Biomarkers of the Metabolic Syndrome and Breast Cancer Prognosis. Cancers. 2010; 2(2):721-739.

Chicago/Turabian Style

Zhu, Qiu-Li; Xu, Wang-Hong; Tao, Meng-Hua. 2010. "Biomarkers of the Metabolic Syndrome and Breast Cancer Prognosis." Cancers 2, no. 2: 721-739.



Cancers EISSN 2072-6694 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert